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Abstract 
Implantation rates of the SynCardia Total Artificial Heart (TAH) system is growing 
owing to the increasing incidence of biventricular heart failure and the limited 
number of transplantable hearts. Among the complications associated with the 
device, atrial tamponade is an emergent condition that requires immediate 
attention. Atrial tamponade occurs when increasing pericardial hemorrhage leads 
to atrial compression that produces tamponade physiology and compromises 
cardiac output. Unfortunately to our knowledge, information concerning the early 
manifestations of tamponade in TAH patients is extremely scarce. Previous 
reports have focused on decreased cardiac output as an indicator of tamponade. 
However, other presentations including pulmonary decompensation are largely 
undescribed. This case provides a valuable account of the early manifestations 
of atrial tamponade observed prior to diminished cardiac output. 
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Background 
Congestive heart failure is a serious cause of morbidity and mortality that affects 
1 to 2% of the developed world and 23 million people worldwide.1,2,3 Initial 
modalities of treating heart failure are focused primarily on pharmacological 
therapy.2 However, the disease process is generally progressive and leads to 
worsening heart failure with symptoms refractory to medical management.2 The  
growing advanced heart failure population has generated a need for additional 
therapies. Cardiac transplantation has been utilized as a definitive form of 
therapy for many years.1,2 Unfortunately, the number of available donor hearts is 
limited and the population of eligible transplant candidates is consistently 
rising.2,3  As a result, implantable devices have emerged as a viable option for 
severe biventricular heart failure. These devices have served as a bridge to 
cardiac transplantation and helped decrease the annual mortality of patients 
awaiting donor hearts.2,3 Devices have also been implanted in patients as 
destination therapy.2 Currently, ventricular assist devices (VADs) and artificial 
hearts are the primary available options.2,3  
 
The SynCardia Total Artificial Heart (TAH) is the only implantable device 
approved by the United States Food and Drug Administration (FDA) for use in 
patients suffering from severe biventricular failure.4 The device functions by 
replacing the native ventricles with synthetic chambers that maintain pulsatile 
blood flow. 4 Each synthetic chamber is composed of an air diaphragm and blood 
diaphragm separated by two dividing diaphragms. The inflation and deflation of 
the air chamber via the external console facilitates the emptying and filling of the 
blood diaphragm. This orchestrated activity functions to maintain pulsatile flow. 
The blood enters the ventricle from the atria passively via an inflow connector. 
Next, the blood exits the ventricle with inflation of the air diaphragm through the 
outflow connector. The outflow tracts attach to the pulmonary artery or aorta.4 
Mechanical valves mounted within the inflow and outflow connectors maintain 
unidirectional flow. An external console delivers power and compressed air to the 
device through a driveline tunneled out of the anterior chest. The console 
monitors device function and initiates preprogrammed alarms during any 
malfunction.4  
 
Among the possible complications arising from the use of the TAH, atrial 
tamponade is especially serious. It is a rare but potentially fatal occurrence in this 
fragile population. 4,5 Prompt identification and intervention is crucial to prevent 
hemodynamic collapse. 4,5,6 The SynCardia system has intrinsic alarms that 
sound in response to decreased cardiac output states, such as tamponade. 
Although these alarms are valuable tools to the clinician, they are not a substitute 
for clinical acumen. Literature evaluating the early manifestations of this 
phenomenon in patients implanted with TAHs is lacking. We present a case of 
atrial tamponade after TAH placement to emphasize the early clinical expression 
of this disease process and stress the value of clinical judgment.  
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Case Presentation 
A 61-year-old man was transferred to our center with biventricular failure 
refractory to medical management.  Upon arrival, the patient was alert, 
hypotensive (blood pressure 70/40 mmHg), tachycardic (110 beats per minute), 
tachypneic (25 respirations per minute), and hypoxic (oxygen saturation bellow 
88% breathing room air). The patient required support with dopamine, 
neosynephrine, and oxygen supplementation. He had endured six months of 
worsening shortness of breath and pitting edema despite increased medical 
therapy. His medical history included obesity, diabetes mellitus, hyperlipidemia, 
hypertension, coronary artery bypass graft surgery, and automatic implantable 
cardioverter defibrillator placement for a depressed ejection fraction. There was 
no family or social history related to his severe heart failure.  
Due to his decompensated state and need for cardiac support, a TandemHeart 
(CardiacAssist Inc.) peripheral ventricular assist device was utilized as a bridge 
to decision. The device facilitated weaning of vasopressor support and 
hemodynamic stabilization. Unfortunately, the patient could not be taken off of 
TandemHeart support as a result of biventricular failure. Furthermore, he did not 
meet eligibility for cardiac transplantation owing to worsening multi-organ system 
failure. The patient needed a bridge to facilitate clinical improvement before 
reevaluation for transplant candidacy. Twelve days after presentation, the patient 
underwent explanation of the TandemHeart and implantation with the SynCardia 
TAH that was intended as a bridge to definitive therapy. 
The Syncardia device was implanted with a total cardiopulmonary bypass time of 
178 minutes and an aortic crossclamp time of 148 minutes.  His estimated blood 
loss was one liter and required transfusion with four units of packed red blood 
cells, three “jumbo” packs (400 mL each) of fresh frozen plasma, and one jumbo 
pack of platelets. The procedure was free of major complications and the patient 
was extubated 24 after surgical closure. His postoperative chest radiograph 
showed the SynCardia device in place with no pneumonic process (Figure 1). His 
chest tubes were removed four days after closure when the drainage significantly 
decreased and the air leaks had resolved. Additionally, lab values noted 
leukocytosis and anemia that was presumed to be the result of the extensive 
surgery and were appropriately managed. Improving the patient’s strength and 
ambulation became the focus of his postimplantation course.  
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Figure 1: Chest radiograph post-operative day 3 after extubation.    
Twelve days after device placement, the patient was noted to be pale, lethargic, 
and diaphoretic. No elevation in temperature was observed. Combined with 
these symptoms, the patient expressed feelings of clinical deterioration and 
increased shortness of breath. Assessment of vital signs revealed hypotension 
with a mean arterial pressure (MAP) of 45 mmHg and tachypnea with 25 
respirations per minute. Laboratory evaluation revealed a lactate elevation 
suggesting insufficient end organ perfusion (Figure 2) and decreased hemoglobin 
concentrations, (Figure 3).  However, the SynCardia module reported no alarms 
or reduction in cardiac output overnight or during the early morning. Because the 
clinical management team was concerned that there may have been an 
intrathoracic etiology for his acute clinical change, a chest radiograph was 
ordered. Alarms noting decreased fill volume and cardiac output from the 
SynCardia console were noted only after the patient clinically worsened and the 
chest radiograph was obtained. A new left pleural effusion (Figure 4) was 
identified, which prompted emergency chest tube placement and drainage of 700 
milliliters of serosanguinaous fluid. A computer tomography (CT) scan of the 
chest was ordered for further investigation into the cause of the pleural effusion. 
The CT scan revealed an aortic root graft aneurysm of 43 millimeters and 
increased complex mediastinal fluid with areas of attenuation indicative of 
possible hemorrhage and tamponade (Figures 6 and 7). A transesophageal 
echocardiogram was also obtained and confirmed the presence of atrial 
tamponade and noted left atrial compression (Figures 8 and 9).   
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Figure 2: Trend of lactic acidosis on the day of atrial tamponade (8/18/14). 
 
 
Figure 3: Trend of hemoglobin on the day of atrial tamponade (8/18/14). 
 
 
Figure 4: Portable chest radiograph of the patient on the day of atrial 
tamponade (8/18/14).  
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Figure 5:  Syncardia console measurements on day of atrial tamponade. 
 
 
 
 
Figure 6. Computed tomography scan showing hemorrhage and pericardial 
effusion in transverse plane.  
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Figure 7. Computed tomography scan showing hemorrhage and pericardial 
effusion in coronal plane.  
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Figure 8. Trasesophageal echocardiogram showing left atrial compression 
from atrial tamponade. A: Blood in the pericardium. B: Right atria. C: 
Compressed left atrium. D: Pulmonary vein.   
 
 
Figure 9. Chest radiograph after surgical evacuation of pericardial effusion 
and control of intrathoracic bleeding.  
The patient was promptly taken to the operating theater for evacuation of any 
pericardial effusion. Blunt dissection identified the effusion and prompted surgical 
release of the large hemorrhagic collection. Multiple pericardial clots were 
removed, revealing evidence of ongoing bleeding from the aortic suture line to 
the SynCardia device. This area was noted to be oozing in several places on the 
posterior aspect of the heart. Bleeding was controlled with several interrupted 
sutures and the aortic graft was collared with a second Dacron graft. This 
collaring approach served to create two bands around the distal aorto-graft 
anastomosis. The patient tolerated the procedure well with resolution of atrial 
tamponade and pleural effusion.  
Discussion 
SynCardia TAH use in patients suffering from severe biventricular failure has 
steadily increased.7,8,9 Atrial tamponade is a serious complication that inhibits 
cardiac output by preventing atrial filling. The lack of ventricular preload due to 
atrial collapse results in circulatory compromise. This condition requires 
immediate identification and intervention to prevent catastrophic 
ramifications.10,11 In the event of tamponade inducing cardiac arrest in patients 
implanted with a TAH, the primary means of stabilization requires surgical 
evacuation of the pericardial effusion. Chest compressions will not benefit 
patients with atrial tamponade in the presence of a TAH since external force will 
not compress the artificial ventricle. 4 Literature concerning the early 
manifestations of tamponade in TAH implanted patients is largely absent. 
Previous reports have indicated that decreased cardiac output is the primary 
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symptom 4,5,6 Our case report demonstrates the immense value of physical exam 
and clinical acumen in identifying and treating this complication. Tachycardia, 
hypotension, tachypnea, and increased difficulty breathing were the first 
symptoms present in our patient. These findings launched further investigations 
before console alarms noted decreased cardiac output. The early identification of 
thoracic hemorrhage that resulted in a left pleural effusion and atrial tamponade 
allowed our team to intervene and maximize the potential for recovery. The 
evolution of a graft leak to cardiac compromise suggests that there is a spectrum 
of clinical manifestations that may facilitate early tamponade identification. Even 
with the implementation of cutting-edge technology, the fundamentals of good 
clinical practice are invaluable assets in optimizing patient care. This case 
reports early manifestations of atrial tamponade in the presence of SynCardia 
TAH to offer a clinical experience missing in current literature. 
Learning points  
• Atrial tamponade in patients with total artificial hearts can be lethal.  
• Prompt identification and surgical evacuation decrease morbidity and 
mortality.  
• Clinical signs of acute decompensation may precede device alarms.  
• Physical evaluation of the patient cannot be substituted by technological 
applications.  
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